risankizumab
abbvie,boehringer ingelheim
['risan', 'psoriasis']
congress #wcd2023singapore | late-breaker
andrew blauvelt at oregon medical center discussed the results of a phase ii knockout study of high induction dosing of risankizumab (rzb) in pts with moderate-to-severe plaque #psoriasis. about 90% of pts achieved pasi 90 &amp; 2/3 of pts 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource that provides balanced and up-to-date medical education. #Psoriasis #RheumTwitter